Testing treatment for enterococcal heart valve infection
Part of Heart & circulation, Infections clinical trials.
This Phase 4 trial studies treatment for an infection of the heart valves caused by certain enterococcus bacteria. It may help improve how these infections are treated in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an infective endocarditis diagnosis (a heart valve infection).
- The infection is caused by enterococcus bacteria.
- Your diagnosis is based on the hospital’s standard checklist for endocarditis (the modified Duke criteria).
- You are not currently expected to need long-term (chronic) antibiotic suppression after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares taking antibiotics by mouth versus receiving antibiotics through a vein (outpatient IV) for an infection of the heart valve. It’s designed to see whether the oral option can work as well and safely, especially after initial treatment and surgery if needed.
This trial measures how your body handles certain intravenous antibiotics used for endocarditis, an infection of the heart valves. It may help doctors understand the best antibiotic dosing for people with valve infections.
This trial tests if adding bacteriophages (viruses that kill bacteria) to standard antibiotic treatment can help people with a serious heart valve infection called infective endocarditis. It may offer a new way to fight the infection.
This study follows patients diagnosed with infectious endocarditis (a serious infection of the heart valve) to better understand how the condition progresses and what factors affect outcomes. Researchers will use imaging tests and surgical information to track your health over time.
This study looks at why some people with enterococcus bacteria in their blood develop a serious heart infection called endocarditis. Researchers want to learn more about this bacteria to help prevent and treat heart infections.
This trial tests whether a treatment without rifampin works as well as one with rifampin for a type of heart valve infection caused by staph bacteria. It aims to find a simpler and safer option for patients with an infected artificial heart valve.
Hear when a new Enterococcal Endocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.